References
- Altman, A., Mustelin, T., Coggeshall, K.M. (1990). T lymphocyte activation: A biological model of signal transduction. Crit. Rev. Immunol., 10, 347-391.
- Barton, D.P., Blanchard, D.K., Michelini-Norris, B., Nicosia, S.V., Cavanagh, D., Djeu, J.Y. (1993). High serum and ascitic soluble interleukin-2 receptor α levels in advanced epithelial ovarian cancer. Blood, 81(2), 424-429.
- Bien, E., Rapala, M., Krawczyk, M., Balcerska, A. (2010). The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas. J. Cancer Res. Clin. Oncol., 136(2), 293-305.
- Bruijn, H.W., ten Hoor, K.A., van der Zee, A.G. (1998). Serum and cystic fluid levels of soluble interleukin-2 receptor-alpha in patients with epithelial ovarian tumors are correlated. Tumour Biol., 19(3), 160-166.
- Brunetti, G., Bossi, A., Baiardi, P., Jedrychowska, I., Pozzi, U., Bacchella, L., Bernardo, G. (1999). Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy. Lung Cancer, 23, 1-9.
- Chilosi, M., Semenzato, G., Cetto, G., Ambrosetti, A., Fiore-Donati, L., Perona, G., Berton, G., Lestani, M., Scarpa, A., Agostini, C. (1987). Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: Relationship with the effect of recombinant α-interferon therapy on clinical parameters and natural killer in vitro activity. Blood, 70(5), 1530-1535.
- Ferdeghini, M., Gadducci, A., Prontera, C., Malagnino, G., Fanucchi, A., Annicchiarico, C., Facchini, V., Bianchi, R. (1993). Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. Tumour Biol., 14(5), 303-309.
- Gebauer, G., Rieger, M., Jäger, W., Lang, N. (1999). Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors. Anticancer Res., 19(4A), 2509-2511.
- Hunter, V.J., Weinberg, J.B., Haney, A.F., Soper, J.T., Lavin, P., Metsch, L., Knapp, R.C., Bast, R.C. (1990). CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol., 36(2), 161-165.
- Hurteau, J.A., Woolas, R.P., Jacobs, I.J., Oram, D.C., Kurman, C.C., Rubin, L.A., Nelson, D.L., Berchuck, A., Bast, R.C., Mills, G.B. (1995). Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer, 76(9), 1615-1620.
- Jo, S.A., Hwang, S.H., Chang, C.L., Kim, S.Y., Shin, H.J., Chung, J.S., Sol, M.Y., Lee, E.Y. (2010). Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma. Korean J. Lab. Med., 30(6), 600-605.
- Lauria, F., Rondelli, D., Raspadori, D., Zinzani, P.L., Benfenati, D., Pileri, S., Sabattini, E., Tura, S. (1992). Serum soluble interleukin-2 receptor levels in hairy cell leukemia: Correlation with clinical and hematological parameters and with alpha-interferon treatment. Leuk. Lymphoma, 7(1-2), 103-107.
- Lissoni. P., Barni, S., Rovelli, F., Viviani, S., Maestroni, G.J., Conti, A., Tancini, G. (1990). The biological significance of soluble interleukin 2 receptors in solid tumors. Eur. J. Cancer, 26, 33-36.
- Meyer, F., Samson, E., Douville, P., Duchesne, T., Liu, G., Bairati, I. (2010). Serum prognostic markers in head and neck cancer. Clin. Cancer Res., 16(3), 1008-1015.
- Mills, G.B., Zhang, N., Schmandt, R., Fung, M., Greene, W., Mellors, A., Hogg, D. (1991). Transmembrane signalling by interleukin-2. Biochem. Soc. Trans., 19, 277-285.
- Owens, O.J., Taggart, C., Wilson, R., Walker, J.J., McKillop, J.H., Kennedy, J.H. (1993). Interleukin-2 receptor and ovarian cancer. Brit. J. Cancer, 68, 364-367.
- Pavlidis, N.A., Bairaktari, E., Kalef-Ezra, J., Nicolaides, C., Seferiadis, C., Fountzilas, G. (1995). Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients. Int. J. Biol. Markers, 10(2), 75-80.
- Rubin, L.A., Kurman, C.C., Fritz, M.E., Biddison, W.E., Boutin, B., Yarchoan, R., Nelson, D.L. (1985). Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J. Immunol., 135, 3172-3175.
- Rubin, L.A., Nelson, D. (1990). The soluble interleukin-2 receptor: Biology, function and clinical application. Ann. Intern. Med., 113, 619-645.
- Sedlaczek, P., Frydecka, I., Gabryś, M., Van Dalen, A., Einarsson, R., Harłozińska, A. (2002). Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer, 95, 1886-1893.
- Smith, K.A. (1988). Interleukin-2: Inception, impact and implications. Science, 240(4856), 1169-1176.
- Sperner-Unterweger, B., Neurauter, G., Klieber, M., Kurz, K., Meraner, V., Zeimet, A., Fuchs, D. (2011). Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology, 216(3), 296-301.
- Symons, J.A., Wood, N.C., Di Giovine, F.S., Duff, G.W. (1988). Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-I and IL-2 inhibition. J. Immunol., 141(8), 2612-2618.
- Waldmann, T.A. (1991). The interleukin-2 receptor. J. Biol. Chem., 266, 2681-2684.